Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Secretogranin II (SCG2) is a neuroendocrine secretory protein belonging to the granin family, primarily expressed in neuroendocrine cells. It is pivotal for sorting and packaging neuropeptides and hormones within secretory vesicles. SCG2 undergoes proteolytic cleavage to produce active peptides, most notably secretoneurin, which exerts potent angiogenic and chemotactic influences and plays roles in immune cell migration, endothelial function, and neurodevelopment. The protein and its peptides have diagnostic and prognostic relevance, especially in neuroendocrine tumors, cardiovascular diseases, and developmental disorders, but SCG2 itself is not a classical drug target such as an enzyme or receptor
Not applicable (no drugs targeting SCG2). Secretoneurin, a cleavage product, acts as a chemoattractant and modulates endothelial function and angiogenesis, but is not itself the target of a drug mechanism
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Secretogranin II (SCG2).